
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
Under Section 13 or 15(d) of
the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 27, 2007

ResMed Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware
(State or Other Jurisdiction
of Incorporation)

001-15317
(Commission File Number)

98-0152841
(I.R.S. Employer
Identification No.)

14040 Danielson Street
Poway, California 92064-6857
(Address of Principal Executive Offices)

(858) 746-2400
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**(b) Departure of Directors or Certain Officers.**

On August 27, 2007, the ResMed Inc. Board of Directors approved a succession plan under which, effective January 1, 2008, Dr. Peter C. Farrell will resign as Chief Executive Officer. Dr. Farrell will continue as Executive Chairman of the Board through June 30, 2008, when he will become non-executive Chairman of the Board.

(c) Appointment of Certain Officers.

Under the succession plan, effective January 1, 2008, Kieran T. Gallahue, 44, will be promoted to Chief Executive Officer.

Mr. Gallahue has been President, ResMed Global, since September 7, 2004. Before that, and beginning in January 2003, Mr. Gallahue was President and Chief Operating Officer of the Americas. Before joining the Company, Mr. Gallahue served as President of Nanogen, Inc., a San Diego-based DNA research and medical diagnostics company. Mr. Gallahue also held the roles of Chief Financial Officer and Vice President of Strategic Marketing for Nanogen. From 1995 to 1997, Mr. Gallahue served as Vice President of the Critical Care Business Unit for Instrumentation Laboratory, where he was responsible for worldwide strategic sales and marketing, and research and development efforts for this business unit. From 1992 to 1995, Mr. Gallahue held a variety of sales and marketing positions within IL. In addition, Mr. Gallahue held various marketing and financial positions within Procter & Gamble and the General Electric Company. Mr. Gallahue is a member of the board of directors of Volcano Corporation, a NASDAQ-listed company focusing on diagnosis and treatment of vascular and structural heart disease. Mr. Gallahue holds a B.A. from Rutgers University and an M.B.A. from Harvard Business School.

(d) Election of Directors.

Under the succession plan, effective January 1, 2008, Mr. Gallahue will be appointed to the Board.

The full text of the press release relating to Mr. Gallahue's promotion to Chief Executive Officer and appointment to the Board, and Dr. Farrell's resignation as Chief Executive Officer, is furnished as Exhibit 99.1 to this Current Report on Form 8-K and will not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section.

Item 9.01 Financial Statements and Exhibits.**(d) Exhibits**

Exhibits:	Description of Document
99.1	Press Release dated August 30, 2007

SIGNATURES

We have authorized the person whose signature appears below to sign this report on our behalf, in accordance with the Securities Exchange Act of 1934.

Date: August 31, 2007

RESMED INC.
(registrant)

By: /s/ David Pendarvis

Name: David Pendarvis

Its: Secretary, Global General Counsel and
Senior Vice President - Organizational Development

ResMed Names Kieran Gallahue as Chief Executive Officer, Effective January 1, 2008.***Dr. Peter Farrell to remain Chairman of the Board***

San Diego, Aug 30, 2007— ResMed Inc. (NYSE:RMD) announced today that its board of directors has unanimously approved a succession plan for executive management of the company. Effective January 1, 2008, Kieran T. Gallahue will be promoted to Chief Executive Officer and will join the board of directors. Mr. Gallahue, 44, will succeed Dr. Peter C. Farrell, 65. As of January 1, 2008, Dr. Farrell will relinquish his position as CEO, but will continue serving as Executive Chairman of the Board until June 30, 2008, when he will become non-executive Chairman.

“Since joining ResMed in 2003, Kieran has demonstrated strong leadership qualities,” said Dr. Farrell. “He has been instrumental in improving our operational execution, targeting our research and development efforts, focusing our commercial teams to better serve patients and customers, while strengthening the depth of our management. He has earned the respect of our employees and customers. He has the full support of myself and the Board, and is the right person to succeed me as ResMed’s Chief Executive Officer.”

“Since founding the company in 1989, I have been passionate about the need to increase awareness of sleep-disordered breathing among both the public and the medical community, as well as the need to increase understanding of the deleterious consequences of the disease if left untreated,” Dr. Farrell continued. “As Chairman, I intend to remain significantly engaged in the Company’s mission and strategy.”

“It is an honor and a privilege to build on the solid foundation of this Company established by one of the industry’s true visionaries,” said Gallahue. “I am excited about the opportunities ahead of us – a vast untapped market, market-leading technology, and a world class team of employees. I appreciate having the confidence of Peter and the Board and look forward to leading the global team to continued success.”

Gallahue joined ResMed in January 2003 as President and Chief Operating Officer of the Americas. He was named President and Chief Operating Officer – ResMed Global, in September 2004. Before joining ResMed, Mr. Gallahue served as President of Nanogen, Inc., a San Diego-based DNA research and medical diagnostics company. In his earlier career, he also worked for Instrumentation Laboratory, Procter & Gamble and the General Electric Company. Mr. Gallahue holds a BA degree from Rutgers University and an MBA from Harvard Business School.

About ResMed

ResMed is a leading manufacturer of medical equipment for the treatment and management of sleep-disordered breathing and other respiratory disorders. We are dedicated to developing innovative products to improve the lives of those who suffer from these conditions and to increasing awareness among patients and healthcare professionals for the potentially serious health consequences of untreated sleep-disordered breathing.

Further information can be obtained by contacting Matthew Borer at ResMed Inc., San Diego, at (858) 746-2280; Brett Sandercock at ResMed Limited, Sydney, on (+612) 8884-2090; or by visiting the Company's multilingual Web site at www.resmed.com.